Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

127.85
-0.0500-0.04%
Post-market: 127.76-0.0900-0.07%19:58 EDT
Volume:3.07M
Turnover:392.43M
Market Cap:8.27B
PE:-52.11
High:128.07
Open:128.07
Low:127.77
Close:127.90
Loading ...

Blueprint Medicines: Positive Earnings Call Highlights Growth

TIPRANKS
·
14 Feb

Strong Market Position and Growth Potential Drive Buy Rating for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines should be bought on any weakness, says Stifel

TIPRANKS
·
14 Feb

Optimistic Growth Potential and Market Expansion Justify Buy Recommendation for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines selloff to be short-lived, says Oppenheimer

TIPRANKS
·
14 Feb

Wedbush Adjusts Price Target on Blueprint Medicines to $128 From $124, Maintains Outperform Rating

MT Newswires Live
·
13 Feb

Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat

Stock Track
·
13 Feb

Blueprint Medicines Price Target Maintained With a $133.00/Share by Needham

Dow Jones
·
13 Feb

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
13 Feb

Blueprint Medicines Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
13 Feb

Earnings Flash (BPMC) Blueprint Medicines Posts Q4 Net Loss $-0.79 a Share, vs. FactSet Est of $-0.67 Loss

MT Newswires Live
·
13 Feb

Blueprint Medicines: Q4 Earnings Snapshot

Associated Press Finance
·
13 Feb

Blueprint Medicines reports Q4 EPS (79c), consensus (71c)

TIPRANKS
·
13 Feb

Blueprint Medicines Forecasts 2025 Global Ayvakit Net Product Revenues Of Approximately $680M-$710M

Benzinga
·
13 Feb

Blueprint Medicines Q4 2024 GAAP EPS $(0.79) Misses $(0.70) Estimate, Sales $146.37M Beat $145.84M Estimate

Benzinga
·
13 Feb

Blueprint Medicines Corp: Anticipate Global Ayvakit Net Product Revenue of Approximately $680 Mln to $710 Mln in 2025

THOMSON REUTERS
·
13 Feb

Blueprint Medicines - Updates Systemic Mastocytosis Franchise Revenue Opportunity to $4 Billion by 2030

THOMSON REUTERS
·
13 Feb

Blueprint Medicines Corp: Expects Further Cash Burn Reduction in 2025

THOMSON REUTERS
·
13 Feb

Blueprint Medicines Corp: Anticipate Global Ayvakit Net Product Revenue of About $680 Mln to $710 Mln in 2025

THOMSON REUTERS
·
13 Feb